These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24239629)

  • 1. Anti-hepatoma human single-chain Fv antibody and adriamycin conjugates with potent antitumor activity.
    Chen L; Liu YH; Li YH; Jiang Y; Xie PL; Zhou GH; Li GC
    Int Immunopharmacol; 2014 Jan; 18(1):20-6. PubMed ID: 24239629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of scFv SA3 against hepatoma fused with enhanced green fluorescent protein and its targeted ability in vivo.
    Huang J; Li Y; Guo F; Tong Y; Wang J; Hu J; Li G
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 36(10):979-86. PubMed ID: 22086009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Targeting therapy with adriamycin-monoclonal antibody (HAb18) conjugate in nude mice with human hepatocellular carcinoma xenografts].
    Sui Y
    Zhonghua Yi Xue Za Zhi; 1992 Jul; 72(7):397-400, 445. PubMed ID: 1330227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Selection and characterization of human scFv antibodies against hepatocellular carcinoma].
    Huang J; Xiao Y; Tong YQ; Guo FJ; Zhou GH; Li YH; Hu JY; Li GC
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Mar; 24(3):256-9. PubMed ID: 18328187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The antitumor effect of adriamycin conjugated with monoclonal antibody against gastric cancer in vitro and in vivo].
    Zhang YT; Wang NQ; Li N; Liu T; Dong ZW
    Yao Xue Xue Bao; 1992; 27(5):325-30. PubMed ID: 1442051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Growth inhibitory effect of adriamycin conjugated to single-chain antibody on human lung adenocarcinoma in vitro].
    Yue WT; Lai BT; Wang H; Zhan XP; Wang Y
    Zhonghua Zhong Liu Za Zhi; 2004 Dec; 26(12):718-21. PubMed ID: 15733387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ad-KDRscFv:sTRAIL displays a synergistic antitumor effect without obvious cytotoxicity to normal tissues.
    Yang L; Guo J; Wang J; Wan S; Yang S; Wang R; Chen W; Peng G; Fang D
    Int Immunopharmacol; 2012 May; 13(1):37-45. PubMed ID: 22406047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
    Sheng W; Shang Y; Li L; Zhen Y
    Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antitumor effect of nanospheres coupled with the anti-human liver cancer monoclonal antibody HAb18].
    Kan HP; Liu ZJ; Tan YF; Lin YX; Li CF; Zhou J
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1503-5. PubMed ID: 18753092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effect of humanized anti-VEGFR-2 ScFv-As2O3-stealth nanoparticles conjugate on growth of human hepatocellular carcinoma: in vitro and in vivo studies.
    Yin XB; Wu LQ; Fu HQ; Huang MW; Wang K; Zhou F; Yu X; Wang KY
    Asian Pac J Trop Med; 2014 May; 7(5):337-43. PubMed ID: 25063057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue directed against epidermal growth factor receptor.
    Sheng W; Shang Y; Miao Q; Li Y; Zhen Y
    Anticancer Drugs; 2012 Apr; 23(4):406-16. PubMed ID: 22205154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Gelatinases-targeting scFv-based Fusion Protein Shows Enhanced Antitumour Activity with Endostar against Hepatoma.
    Gao R; Li L; Shang B; Zhao C; Sheng W; Li D
    Basic Clin Pharmacol Toxicol; 2015 Aug; 117(2):105-16. PubMed ID: 25615234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Preparation of heat shock protein 70 (Hsp70) and idiotypic determinant single-chain antibody (Id-ScFv) in a patient with B-cell chronic lymphatic leukemia (B-CLL) and antitumor effect of peptide complex Hsp70-Id].
    Ye Q; Wang ZH; Qin SK
    Ai Zheng; 2008 Feb; 27(2):133-8. PubMed ID: 18279608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary targeting of recombinant Fv-immunotoxin hscFv(25)-mTNFalpha against hepatocellular carcinoma.
    Zhang J; Liu YF; Yang SJ; Qiao Q; Cheng H; Zhang CS; Ma FC; Guo HZ
    World J Gastroenterol; 2004 Jul; 10(13):1872-5. PubMed ID: 15222026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor cell killing.
    Braslawsky GR; Edson MA; Pearce W; Kaneko T; Greenfield RS
    Cancer Res; 1990 Oct; 50(20):6608-14. PubMed ID: 2208123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Importance of the conjugated antibody for the induction of selective effect of adriamycin conjugated with anti AFP monoclonal antibody and entrapped in liposomes against AFP producing tumors].
    Konno H; Kumai K; Tsubouchi T; Ishibiki K; Abe O; Tadakuma T; Yasuda T; Nagaike K; Hosokawa S; Sakaguchi S
    Gan To Kagaku Ryoho; 1989 Jun; 16(6):2213-7. PubMed ID: 2472119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experimental studies on targeting chemotherapy using adriamycin entrapped in liposomes conjugated with anti-human alpha-fetoprotein monoclonal antibody].
    Suzuki H
    Nihon Geka Gakkai Zasshi; 1991 Mar; 92(3):257-65. PubMed ID: 1711147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A conjugate of an anti-midkine single-chain variable fragment to doxorubicin inhibits tumor growth.
    Zhao S; Zhao G; Xie H; Huang Y; Hou Y
    Braz J Med Biol Res; 2012 Mar; 45(3):230-7. PubMed ID: 22267001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activities of dFv-LDP-AE: An enediyne-energized fusion protein targeting tumor-associated antigen gelatinases.
    Zhong GS; Wu MN; Guo XF; Zhang SH; Miao QF; Zhen YS
    Oncol Rep; 2012 Oct; 28(4):1193-9. PubMed ID: 22797730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.